carvedilol has been researched along with Dizziness in 6 studies
Dizziness: An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Data were retrospectively collected from 23 patients with HF [age 57±18 years, left ventricular ejection fraction (LVEF) 33±15%] who could not increase the dosage of carvedilol because of dizziness or hypotension, defined as systolic blood pressure<90 mmHg." | 7.79 | Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension. ( Asano, Y; Ichibori, Y; Kanzaki, M; Komuro, I; Minamiguchi, H; Mizote, I; Ohtani, T; Sakata, Y; Taniguchi, T, 2013) |
| "Carvedilol was found to be safe, and it significantly reduced cardiac events compared with placebo (18 on carvedilol and 31 on placebo, P < ." | 6.68 | Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. ( Basu, S; Bruckner, T; Lahiri, A; Raval, U; Senior, R; van der Does, R, 1997) |
| "beta-blockers (BB) in the treatment of heart failure (HF) are frequently underprescribed and underdosed, perhaps because of recommendations for office visits at each dose change." | 5.32 | Remote titration of carvedilol for heart failure patients by advanced practice nurses. ( Mischke, L; Moyer-Knox, D; Mueller, TM; Vuckovic, K; Williams, RE, 2004) |
| "Data were retrospectively collected from 23 patients with HF [age 57±18 years, left ventricular ejection fraction (LVEF) 33±15%] who could not increase the dosage of carvedilol because of dizziness or hypotension, defined as systolic blood pressure<90 mmHg." | 3.79 | Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension. ( Asano, Y; Ichibori, Y; Kanzaki, M; Komuro, I; Minamiguchi, H; Mizote, I; Ohtani, T; Sakata, Y; Taniguchi, T, 2013) |
| "Beta-blockers substantially improve survival in patients with chronic heart failure (HF) with left ventricular systolic dysfunction, but concerns about cardiovascular adverse effects may deter physicians from prescribing this therapy." | 2.71 | Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. ( Coffey, CS; Curtis, JP; Foody, JM; Hebert, PR; Ko, DT; Krumholz, HM; Sedrakyan, A, 2004) |
| "The responses to passive orthostasis (tilt provocation at 60 degress for 8 min) were measured in normotensive healthy volunteers with finger-blood-pressure and whole-body impedance cardiography prior to drugs and three days after beginning the medications." | 2.71 | Effects of adrenoceptor blocking drugs on cardiovascular responsiveness to passive orthostasis: a placebo-controlled double-blind study. ( Kähönen, M; Kööbi, T; Nieminen, T; Ylitalo, P; Ylitalo, R, 2005) |
| "Carvedilol was found to be safe, and it significantly reduced cardiac events compared with placebo (18 on carvedilol and 31 on placebo, P < ." | 2.68 | Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. ( Basu, S; Bruckner, T; Lahiri, A; Raval, U; Senior, R; van der Does, R, 1997) |
| "beta-blockers (BB) in the treatment of heart failure (HF) are frequently underprescribed and underdosed, perhaps because of recommendations for office visits at each dose change." | 1.32 | Remote titration of carvedilol for heart failure patients by advanced practice nurses. ( Mischke, L; Moyer-Knox, D; Mueller, TM; Vuckovic, K; Williams, RE, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Taniguchi, T | 1 |
| Ohtani, T | 1 |
| Mizote, I | 1 |
| Kanzaki, M | 1 |
| Ichibori, Y | 1 |
| Minamiguchi, H | 1 |
| Asano, Y | 1 |
| Sakata, Y | 1 |
| Komuro, I | 1 |
| Moyer-Knox, D | 1 |
| Mueller, TM | 1 |
| Vuckovic, K | 1 |
| Mischke, L | 1 |
| Williams, RE | 1 |
| Ko, DT | 1 |
| Hebert, PR | 1 |
| Coffey, CS | 1 |
| Curtis, JP | 1 |
| Foody, JM | 1 |
| Sedrakyan, A | 1 |
| Krumholz, HM | 1 |
| Nieminen, T | 1 |
| Ylitalo, R | 1 |
| Kööbi, T | 1 |
| Ylitalo, P | 1 |
| Kähönen, M | 1 |
| Basu, S | 1 |
| Senior, R | 1 |
| Raval, U | 1 |
| van der Does, R | 1 |
| Bruckner, T | 1 |
| Lahiri, A | 1 |
| Rector, TS | 1 |
3 trials available for carvedilol and Dizziness
| Article | Year |
|---|---|
Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Bradycardia; Carbazoles; Carvedilol; Dizziness; Fatig | 2004 |
Effects of adrenoceptor blocking drugs on cardiovascular responsiveness to passive orthostasis: a placebo-controlled double-blind study.
Topics: Adrenergic alpha-Antagonists; Adrenergic Antagonists; Adrenergic beta-Antagonists; Adult; Carbazoles | 2005 |
Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Dizziness; Echocard | 1997 |
3 other studies available for carvedilol and Dizziness
| Article | Year |
|---|---|
Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Dizziness; Dose-Response Rela | 2013 |
Remote titration of carvedilol for heart failure patients by advanced practice nurses.
Topics: Adrenergic beta-Antagonists; Aged; Bradycardia; Carbazoles; Carvedilol; Clinical Protocols; Cohort S | 2004 |
Measurement of clinical efficacy in studies of heart failure.
Topics: Adrenergic Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Dizziness; Heart Failure; | 1998 |